文献速递血栓与止血

重组人血小板生成素减少慢性肝病合并血小板减少患者的血小板输注需求

Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
PubMed 文献 · Am J Hematol · 2026-07-28

这项多中心、随机(2:1)、双盲、安慰剂对照III期试验纳入120例接受择期侵入性操作的慢性肝病相关血小板减少成人患者,评估rhTPO疗效与安全性。结果显示rhTPO组主要终点达成率85.0%显著高于安慰剂组12.5%(p<0.0001),且避免血小板输注比例更高、血小板计数≥50×10^9/L持续时间更长,安全性与安慰剂相当。

要点

  • rhTPO显著提高择期操作前后持续血小板≥50×10^9/L的患者比例(85.0% vs 12.5%)
  • rhTPO使92.5%患者避免血小板输注,安慰剂组仅25.0%
  • rhTPO组血小板≥50×10^9/L中位持续21.0天,安慰剂组3.0天

核心结论

  • rhTPO对慢性肝病相关血小板减少患者有效且耐受良好,可作为择期侵入性操作前的可行治疗选择。

研究设计与样本

  • 多中心、随机(2:1)、双盲、安慰剂对照III期试验,纳入120例中国成人慢性肝病相关血小板减少(血小板<50×10^9/L)患者。
  • rhTPO组80例,安慰剂组40例,每日一次给药,最长5或7天。

主要发现

  • 主要终点(操作前24小时至操作后7天持续血小板≥50×10^9/L且无需紧急出血处理)达成率rhTPO组85.0% vs 安慰剂组12.5%(p<0.0001)。
  • 术前血小板≥50×10^9/L达成率rhTPO组92.5% vs 安慰剂组20.0%(p<0.0001)。
  • 避免血小板输注比例rhTPO组92.5% vs 安慰剂组25.0%(p<0.0001)。
  • 血小板≥50×10^9/L中位持续时间rhTPO组21.0天 vs 安慰剂组3.0天(p=0.0007)。
  • 治疗相关TEAE发生率两组均为12.5%,未报告治疗相关严重不良事件。

关键数值与推荐

  • 主要终点:操作前24小时至操作后7天持续血小板计数≥50×10^9/L,且无需紧急出血处理。
  • 纳入标准:慢性肝病相关血小板减少,血小板计数<50×10^9/L。

临床怎么用

  • 慢性肝病合并血小板减少(<50×10^9/L)患者行择期侵入性操作前可考虑使用rhTPO提升血小板并减少输注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic liver disease (CLD)-related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD-related thrombocytopenia who were undergoing elective invasive procedures. In this multicenter, randomized (2:1), double-blind, placebo-controlled phase III trial, 120 adult Chinese patients with CLD-related thrombocytopenia (platelet count < 50 × 109/L) received rhTPO (n = 80) or placebo (n = 40) once daily for up to 5 or 7 days. The primary endpoint was the proportion of patients with sustained platelet counts ≥ 50 × 109/L from 24 h before invasive procedure to 7 days post-procedure, without requiring emergency bleeding management. The primary endpoint was achieved by 85.0% of patients in the rhTPO group versus 12.5% in the placebo group (p < 0.0001). Preoperatively, platelet counts ≥ 50 × 109/L were achieved in 92.5% and 20.0% of patients in the rhTPO and placebo groups, respectively (p < 0.0001). Platelet transfusion was avoided in 92.5% of rhTPO-treated patients versus 25.0% of placebo-treated patients (p < 0.0001). The median duration of platelet counts ≥ 50 × 109/L was significantly longer with rhTPO than with placebo (21.0 vs. 3.0 days, p = 0.0007). Treatment-related treatment-emergent adverse events (TEAEs) occurred in 12.5% of patients in both the rhTPO and placebo groups. No treatment-related serious adverse events were reported. Overall, rhTPO was effective and well tolerated in patients with CLD-related thrombocytopenia and may represent a viable therapeutic option for those undergoing elective invasive procedures. Trial Registration: www.chinadrugtrials.org.cn: number CTR20230919.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Han Y, Lin N, Xu J, et al. Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Am J Hematol. 2026. PMID: 42517686. doi:10.1002/ajh.70444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。